These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 15160564)
1. [Better prognosis and favorable tumor stages in patients with invasive breast mammary carcinoma after introduction of the mass screening of breast cancer in Tilburg, the Netherlands]. Groenendijk RP; Bult P; Wobbes T Ned Tijdschr Geneeskd; 2004 May; 148(19):961; author reply 961-2. PubMed ID: 15160564 [No Abstract] [Full Text] [Related]
2. Current management of primary breast cancer. Part I: Screening, diagnosis, staging and local treatment of stage I and II disease. Lopez MJ; Andriole DP Mo Med; 1990 Sep; 87(9):684-90. PubMed ID: 2215472 [TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and monitoring of breast cancer screening programs]. Paci E; Day NE Epidemiol Prev; 1995 Dec; 19(65):310-7. PubMed ID: 8852080 [TBL] [Abstract][Full Text] [Related]
5. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Li CI; Malone KE; Saltzman BS; Daling JR Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Reinier KS; Vacek PM; Geller BM Breast Cancer Res Treat; 2007 Jul; 103(3):343-8. PubMed ID: 17063272 [TBL] [Abstract][Full Text] [Related]
7. Screening for breast cancer. Duffy SW; Smith RA; Gabe R; Tabár L; Yen AM; Chen TH Surg Oncol Clin N Am; 2005 Oct; 14(4):671-97. PubMed ID: 16226686 [TBL] [Abstract][Full Text] [Related]
8. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090 [TBL] [Abstract][Full Text] [Related]
9. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400 [TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and tumor grading in primary breast cancer patients: an analysis of 158 needle core biopsies. Vameşu S Rom J Morphol Embryol; 2006; 47(3):251-7. PubMed ID: 17308684 [TBL] [Abstract][Full Text] [Related]
11. [Guidelines concerning breast pathology in the course of mammographic screening programs. Working group on "Breast pathology in mammographic screening programs" of the European Communities]. Bianchi S; Sapino A; Bussolati G Pathologica; 1997 Jun; 89(3):234-55. PubMed ID: 9380418 [No Abstract] [Full Text] [Related]
12. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Kattan MW; Giri D; Panageas KS; Hummer A; Cranor M; Van Zee KJ; Hudis CA; Norton L; Borgen PI; Tan LK Cancer; 2004 Dec; 101(11):2509-15. PubMed ID: 15495180 [TBL] [Abstract][Full Text] [Related]
13. Dependable social relationships predict overall survival in Stages II and III breast carcinoma patients. Weihs KL; Simmens SJ; Mizrahi J; Enright TM; Hunt ME; Siegel RS J Psychosom Res; 2005 Nov; 59(5):299-306. PubMed ID: 16253620 [TBL] [Abstract][Full Text] [Related]
14. National breast cancer audit: overview of invasive breast cancer management. Cuncins-Hearn AV; Boult M; Babidge W; Zorbas H; Villanueva E; Evans A; Oliver D; Kollias J; Reeve T; Maddern G ANZ J Surg; 2006 Aug; 76(8):745-50. PubMed ID: 16916399 [TBL] [Abstract][Full Text] [Related]
15. Comparison of cancer registry and clinical data as predictors for breast cancer survival. Seppänen J; Heinävaara S; Holli K; Hakulinen T Cancer Causes Control; 2008 Dec; 19(10):1299-304. PubMed ID: 18752035 [TBL] [Abstract][Full Text] [Related]
16. [The yield of breast cancer screening: the importance of observational data and the problems of bias]. Giard RW Ned Tijdschr Geneeskd; 2004 Feb; 148(8):352-5. PubMed ID: 15032087 [TBL] [Abstract][Full Text] [Related]
17. [40 years breast carcinoma treatment in the Neubrandenburg region.Can an increase in prognostically more favorable stages be detected?]. Rühle H; Grobe N; Balschat S; Ernst KF; Dewitz D; Winkler L Z Arztl Fortbild Qualitatssich; 1997 Mar; 91(2):135-7. PubMed ID: 9244654 [TBL] [Abstract][Full Text] [Related]
18. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening? Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971 [TBL] [Abstract][Full Text] [Related]
19. Survival from breast cancer in England and Wales up to 2001. Leary A; Smith IE Br J Cancer; 2008 Sep; 99 Suppl 1(Suppl 1):S56-8. PubMed ID: 18813261 [No Abstract] [Full Text] [Related]
20. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]